Revenio Group Corporation: Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act
Revenio Group Corporation | Stock Exchange Release | February 14, 2025 at 16:00:00 EET
Revenio Group Corporation has received the following notification pursuant to Chapter 9, section 5 of the Securities Markets Act (”SMA”), according to which William Demant Invest A/S voting rights in Revenio Group exceeded above 20 percent on February 13, 2025.
Total position of William Demant Invest A/S according to the notification:
| % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 20.02742% | 20.02742% | 26,681,116 | |
| Position of previous notification (if applicable) | 15.10% | 15.10% |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
| Class/type of shares, ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009010912 | 5,343,539 | - | 20.02742% | - |
| SUBTOTAL A | 5,343,539 | 20.02742% | ||
For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
Distribution
Nasdaq Helsinki Ltd
Financial Supervisory Authority (FIN-FSA)
Main media
www.reveniogroup.fi/en
Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.
In 2024, the Group’s net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.